Ozagrel sodium

Ozagrel sodium, in the structure of sodium salt of antiplatelet agglutination agent Ozagrel, is an inhibitor of Thromboxane (TXA) synthetase, which can selectively inhibit thromboxane synthetase and TXA synthesis, hence inhibiting the manufacturing of TXA2 and advertising the manufacturing of Prostacyclin (PGI2), and has the impact of anti platelet aggregation and relieving vasospasm. It can inhibit cerebral embolism and cerebral vasospasm. After a single intravenous injection, the blood disappears quickly, and the steady blood drug awareness is reached after non-stop administration for two hours. After stopping the administration for 24 hours, it is in most cases discharged.